Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.7861/clinmed.2020-0309 http://scihub22266oqcxt.onion/10.7861/clinmed.2020-0309 33144402!7850220!33144402     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Med+(Lond) 2021 ; 21 (1): e84-e87 Nephropedia Template TP {{tp|p=33144402|t=2021. Rationale for the use of sphingosine analogues in COVID-19 patients |pdf=|usr=}}{{33144402}} gab.com Text Rationale for the use of sphingosine analogues in COVID-19 patients JO: Clin Med (Lond) http://www.kidney.de/pget.php?&tw=1&pmid=33144402 #FOAvip Despite the recent announcement of promising drug candidates to treat COVID-19, there is currently no effective antiviral drug or vaccine. There is strong evidence that acute lung injury/acute respiratory distress syndrome (ALI/ARDS), likely triggered by a cytokine storm, is responsible for the severity of disease seen in COVID-19 patients. In support of this hypothesis, pilot studies using IL-6 receptor inhibitors such as tocilizumab have shown promising results. Therefore, the use of drugs or cocktails of drugs with broader ability to inhibit these cytokine receptors is likely to be effective. In this article, we propose the use of sphingosine analogues, which have been shown to mitigate acute lung damage in animal models of ALI/ARDS, as early adjuvant therapies to prevent and/or mitigate the cytokine response in COVID-19 patients. This proposal is based on the ability of these drugs to decrease the production of IL-6 and other cytokines. The potential application of fingolimod (FTY720), the oldest sphingosine analogue approved for the treatment of multiple sclerosis, in the early stages of COVID-19 is discussed in more detail as a prototype drug. Twit Text FOAVip Rationale for the use of sphingosine analogues in COVID-19 patients ????Clin Med (Lond) http://www.kidney.de/pget.php?&tw=1&pmid=33144402 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33144402 #FOAvip English Wikipedia <ref>{{Cite pmid|33144402}}</ref> Rationale for the use of sphingosine analogues in COVID-19 patients #MMPMID33144402 Tasat DR; Yakisich JS Clin Med (Lond) 2021[Jan]; 21 (1): e84-e87 PMID33144402show ga Despite the recent announcement of promising drug candidates to treat COVID-19, there is currently no effective antiviral drug or vaccine. There is strong evidence that acute lung injury/acute respiratory distress syndrome (ALI/ARDS), likely triggered by a cytokine storm, is responsible for the severity of disease seen in COVID-19 patients. In support of this hypothesis, pilot studies using IL-6 receptor inhibitors such as tocilizumab have shown promising results. Therefore, the use of drugs or cocktails of drugs with broader ability to inhibit these cytokine receptors is likely to be effective. In this article, we propose the use of sphingosine analogues, which have been shown to mitigate acute lung damage in animal models of ALI/ARDS, as early adjuvant therapies to prevent and/or mitigate the cytokine response in COVID-19 patients. This proposal is based on the ability of these drugs to decrease the production of IL-6 and other cytokines. The potential application of fingolimod (FTY720), the oldest sphingosine analogue approved for the treatment of multiple sclerosis, in the early stages of COVID-19 is discussed in more detail as a prototype drug. |*COVID-19 Drug Treatment[MESH] |*SARS-CoV-2[MESH] |COVID-19/epidemiology/metabolism[MESH] |Cytokines/*metabolism[MESH] |Fingolimod Hydrochloride/*therapeutic use[MESH] |Humans[MESH] |Sphingosine 1 Phosphate Receptor Modulators/therapeutic use[MESH]Rationale for the use of sphingosine analogues in COVID-19 patients (epmc).pdf DeepDyve Pubget Overpricing